Unlike statin’s anti-thrombotic ability, PCSK9 inhibitors were found to reducethe risk of ischemic stroke while having no association with HS (RR = 0.93; 95%CI: 0.58–1.51) in a meta-analysis involving 5 PCSK9 inhibitor RCTs (76,140patients) [21]. The gene discussed is PCSK9; the disease is ischemic stroke.